ERBB2 and breast carcinoma: Above 85 % of the countries in the regions of the Americas, Europe and South-East Asia had all components for therapies of advanced breast cancer (except HER2+), while -on average- 40 % of the countries in the Eastern Mediterranean region and Africa did not have those (Fig. 3b).